Society states company's drug-device combination technology shown to be safe and effective as autograft replacement with compelling clinical evidence .
Find out moreMedTech Outlook’s Top 10 Orthopedic Solution Providers.
Find out moreThe finalists are in for the 10th annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical and medical device industries’ most influential innovators.
Find out moreProprietary synthetic small peptide technology (P-15) is being evaluated in patients across the U.S. with degenerative disk disease
Find out moreFunding will accelerate commercialization and U.S. lumbar trial for i-FACTOR™ Peptide Enhanced Bone Graft
Find out moreBest New Surgical Technology Solution
Find out moreSingle-center randomized trial is measuring the efficacy of i-FACTOR in lumbar posterolateral spine surgery
Find out moreRapid market adoption highlights advantages of synthetic small peptide technology, one of only two PMA approved bone graft supported by Level 1 human clinical data
Find out moreCompany announces exhibit at North American Spine Society 2017 annual meeting
Find out moreResults published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years.
Find out more